MedTrace Logo

Remifentanil Minimum Effective Dose for Children Intubation Without Neuromuscular Blockade

NCT02454868 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-07-19

No results posted yet for this study

Summary

Introduction: remifentanil's optimal dose for children intubation without neuromuscular blockade is unknown. Method: phase IV adaptative trial using Dixon's up-and-down method for modeling remifentanil's dose-response curve for adequate intubation conditions as defined by previous studies.

Conditions

  • Underdosing of Unspecified General Anesthetics

Interventions

DRUG

Remifentanil

Remifentanil for intubation without neuromuscular blockade

Sponsors & Collaborators

  • University of Brasilia

    collaborator OTHER

  • Brasilia University Hospital

    lead OTHER

Principal Investigators

  • Catia S Goveia, MSc · University of Brasilia

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
9 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2016-07-31
Completion
2016-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02454868 on ClinicalTrials.gov